Trial · NCT07903350
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
NCT07903350, Phase 4, Recruiting, Epicentre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies. Trials, record NCT07903350. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903350
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
- NCT number
- NCT07903350
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 20,000 participants, estimated
- Lead sponsor
- Epicentre
- Conditions
- Ebola, Bundibugyo Virus Disease (BVD)
- Interventions
- ERVEBO Vaccination
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Case fatality among laboratory-confirmed BVD cases hospitalized in Ebola health facilities | Up to 6 months after enrolment | Effectiveness of ERVEBO® in reducing case fatality among laboratory-confirmed Bundibugyo virus disease (BVD) cases hospitalized in Ebola health facilities. |
| Secondary | Incidence of BVD-attributable death | Up to 6 months after enrollment | Incidence of BVD-attributable death among enrolled frontline workers during follow-up, including deaths occurring in Ebola health facilities and in the community |
| Secondary | Cumulative incidence of laboratory-confirmed BVD | Up to 6 months | Cumulative incidence of symptomatic laboratory-confirmed BVD among vaccinated versus unvaccinated frontline workers. |
| Secondary | Test-negative vaccine effectiveness | Up to 12 months | Proportion of vaccinated frontline workers among laboratory-confirmed BVD cases compared with BVD-negative symptomatic frontline workers presenting to Ebola health facilities. |
| Secondary | Severe disease among confirmed BVD cases | Day 1 | Proportion of laboratory-confirmed BVD cases presenting with high viral load at admission, measured by low PCR cycle-threshold (Ct) value, a marker of severe disease and mortality. |
| Secondary | Serious adverse events (SAEs) | 1 month after vaccination | Proportion of vaccinated participants experiencing at least one serious adverse event (SAE) during the safety follow-up period. |
| Secondary | Pregnancy and delivery outcomes among pregnant participants receiving ERVEBO® | 2 months after vaccination | Proportion of pregnancies with at least one adverse pregnancy or delivery outcome among pregnant participants receiving ERVEBO®. Adverse outcomes include spontaneous abortion, stillbirth, elective termination, congenital anomalies, neonatal death and maternal death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903350
GET https://conductscience.org/api/trials/v1/NCT07903350/registered